SaveHealth reports on psoriatic arthritis medications, detailing options like DMARDs, biologics, and NSAIDs, including their ...

Matching weight loss tools to the dominant drivers of weight regulation can lead to more effective, durable, and personalized ...

Scientists are literally turning back the clocks in our cells, with the first drugs about to go to human trials ...

Outlook Therapeutics received notice that the Food and Drug Administration can't approve its biologics license application for a drug designed to treat macular degeneration.

Outlook Therapeutics shares slid after the company's macular degeneration drug was once again rejected by the Food and Drug Administration. The stock dropped 71% to 45 cents a share in after-hours ...

KORU Medical Systems, Inc.KRMD recently announced that it has submitted a 510(k) premarket notification for FDA clearance to ...

Adderall, Ritalin and other stimulants prescribed for attention-deficit/hyperactivity disorder seem to work on brain areas ...

With a Dec. 15 executive order, President Donald Trump became the first U.S. president to classify a narcotic as a weapon of ...

Matthew Herper covers medical innovation — both its promise and its perils. It has been a tough year for medicine. The U.S.

Police have registered a case and initiated an investigation. Police officials confirmed that no note was recovered from the ...

The clinical-stage biotechnology company is seeking regulatory clearance to begin clinical trials of CYPS317, an allogeneic fibroblast spheroid-based therapy developed for moderate to severe psoriasis ...

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it has completed the rolling submission of its Biologics License Application (BLA) ...